Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease. 2021

Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, United Kingdom.

Parkinson's disease (PD) is associated with cholinergic dysfunction, although the role of M1 and M4 receptors remains unclear. To investigate spatial covariance patterns of cholinergic muscarinic M1 /M4 receptors in PD and their relationship with cognition and motor symptoms. Some 19 PD and 24 older adult controls underwent 123 I-iodo-quinuclidinyl-benzilate (QNB) (M1 /M4 receptor) and 99m Tc-exametazime (perfusion) single-photon emission computed tomography (SPECT) scanning. We implemented voxel principal components analysis, producing a series of images representing patterns of intercorrelated voxels across individuals. Linear regression analyses derived specific M1 /M4 spatial covariance patterns associated with PD. A cholinergic M1 /M4 pattern that converged onto key hubs of the default, auditory-visual, salience, and sensorimotor networks fully discriminated PD patients from controls (F1,41  = 135.4, P < 0.001). In PD, we derived M1 /M4 patterns that correlated with global cognition (r = -0.62, P = 0.008) and motor severity (r = 0.53, P = 0.02). Both patterns emerged with a shared topography implicating the basal forebrain as well as visual, frontal executive, and salience circuits. Further, we found a M1 /M4 pattern that predicted global cognitive decline (r = 0.46, P = 0.04) comprising relative decreased binding within default and frontal executive networks. Cholinergic muscarinic M1 /M4 modulation within key brain networks were apparent in PD. Cognition and motor severity were associated with a similar topography, inferring both phenotypes possibly rely on related cholinergic mechanisms. Relative decreased M1 /M4 binding within default and frontal executive networks could be an indicator of future cognitive decline. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015899 Tomography, Emission-Computed, Single-Photon A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image. CAT Scan, Single-Photon Emission,CT Scan, Single-Photon Emission,Radionuclide Tomography, Single-Photon Emission-Computed,SPECT,Single-Photon Emission-Computed Tomography,Tomography, Single-Photon, Emission-Computed,Single-Photon Emission CT Scan,Single-Photon Emission Computer-Assisted Tomography,Single-Photon Emission Computerized Tomography,CAT Scan, Single Photon Emission,CT Scan, Single Photon Emission,Emission-Computed Tomography, Single-Photon,Radionuclide Tomography, Single Photon Emission Computed,Single Photon Emission CT Scan,Single Photon Emission Computed Tomography,Single Photon Emission Computer Assisted Tomography,Single Photon Emission Computerized Tomography,Tomography, Single-Photon Emission-Computed
D060825 Cognitive Dysfunction Diminished or impaired mental and/or intellectual function. Cognitive Disorder,Mild Cognitive Impairment,Cognitive Decline,Cognitive Impairments,Mental Deterioration,Cognitive Declines,Cognitive Disorders,Cognitive Dysfunctions,Cognitive Impairment,Cognitive Impairment, Mild,Cognitive Impairments, Mild,Decline, Cognitive,Declines, Cognitive,Deterioration, Mental,Deteriorations, Mental,Disorder, Cognitive,Disorders, Cognitive,Dysfunction, Cognitive,Dysfunctions, Cognitive,Impairment, Cognitive,Impairment, Mild Cognitive,Impairments, Cognitive,Impairments, Mild Cognitive,Mental Deteriorations,Mild Cognitive Impairments
D018678 Cholinergic Agents Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. Acetylcholine Agent,Acetylcholine Agents,Cholinergic,Cholinergic Agent,Cholinergic Drug,Cholinomimetic,Cholinomimetics,Muscarinic,Muscarinic Agent,Muscarinic Agents,Nicotinic Agent,Nicotinic Agents,Cholinergic Drugs,Cholinergic Effect,Cholinergic Effects,Cholinergics,Muscarinic Effect,Muscarinic Effects,Muscarinics,Nicotinic Effect,Nicotinic Effects,Agent, Acetylcholine,Agent, Cholinergic,Agent, Muscarinic,Agent, Nicotinic,Agents, Acetylcholine,Agents, Cholinergic,Agents, Muscarinic,Agents, Nicotinic,Drug, Cholinergic,Drugs, Cholinergic,Effect, Cholinergic,Effect, Muscarinic,Effect, Nicotinic,Effects, Cholinergic,Effects, Muscarinic,Effects, Nicotinic

Related Publications

Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
August 2016, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
May 1998, The Journal of biological chemistry,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
March 2016, Nature,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
February 2008, Neurobiology of learning and memory,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
June 2020, Psychiatry research,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
January 2014, Neuropsychiatric disease and treatment,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
December 2022, Lancet (London, England),
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
December 2019, Drug discovery today,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
February 1993, Molecular pharmacology,
Sean J Colloby, and Pradeep J Nathan, and Geor Bakker, and Rachael A Lawson, and Alison J Yarnall, and David J Burn, and John T O'Brien, and John-Paul Taylor
June 2016, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Copied contents to your clipboard!